Asthma-COPD overlap is not a homogeneous disorder: further supporting data

Respiratory Research

Letter to the Editor

Luis Pérez-de-Llano¹  Borja G. Cosio² 

[1] Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain;Pneumology Service, Hospital Universitario Lucus Augusti, Calle Dr Ulises Romero n° 1. 27003, Lugo, Spain;Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain;

关键词: Eosinophils;    Periostin;    COPD;    Asthma;    Asthma-COPD overlap;    ACO;   

DOI  :  10.1186/s12931-017-0667-x

 received in 2017-06-23, accepted in 2017-10-17,  发布年份 2017

来源: Springer

【 摘 要 】

Asthma-COPD ovelap (ACO) is an umbrella term that encompasses patients with COPD and eosinophilic inflammation (e-COPD) and smoking asthmatics with non-fully reversible airflow obstruction (SA). We compared the clinical characteristics and the inflammatory profile of e-COPD and SA. Patients classified as e-COPD were older and more often male and showed significantly impaired pulmonary function (likely explained by a heavier smoking habit). On the contrary, SA had more atopic features, more reversibility of airflow obstruction and higher IgE levels. The concentrations of IL-5, IL-13, IL-8, IL-6, TNF-α, IL17 in serum were similar between the 2 groups. However, Th2-related biomarkers (periostin, FeNO and blood eosinophils) shower higher median values in e-COPD patients. Our findings reinforce the notion that ACO is a heterogeneous disorder and, as a consequence, it might be unacceptable to offer the same treatment for two related but different conditions.

【 授权许可】

CC BY   
© The Author(s). 2017